Biology subjects

Chang, H.-K.

Publications and source records attributed to Chang, H.-K..

3 recordsLinked to original sources

bioRxiv2026

Identification of functional non-coding variants affecting Alzheimer's disease risk by Massively Parallel Reporter Assay

The majority of genetic risk variants for late-onset Alzheimers disease (LOAD) reside within non-coding genomic regions, suggesting they exert pathogenic effects by disrupting transcriptional regulatory programs. To systematically identify functional variants, we performed an unbiased, high-throughput Massively Parallel Reporter Assay (MPRA) in the THP-1 human monocytic cell line, screening 2,231 SNPs across 24 LOAD GWAS loci. We identified 62 variants exhibiting significant allele-specific transcriptional regulatory output, including rs636317 in the MS4A locus. The risk allele of rs636317 disrupts a CTCF binding motif, altering fine-scale chromatin looping. To validate these findings, we employed CRISPR/Cas9 to generate an allele-specific deletion of the rs636317 T allele in H9 human embryonic stem cells. Monocytes differentiated from these edited cells displayed increased expression of MS4A4E, MS4A6A, and TREM2, along with highly elevated levels of soluble TREM2 (sTREM2). These results provide a mechanistic link between a non-coding genetic variant, transcriptional regulation of the MS4A family, and TREM2-mediated immune responses in Alzheimers disease pathogenesis.

genetics↗

bioRxiv2024

Single-Cell RNA-Seq Reveals Adventitial Fibroblast Alterations during Mouse Atherosclerosis

BackgroundAtherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality in the western world despite the success of lipid lowering therapies, highlighting the need for novel lipid-independent therapeutic strategies. Genome-wide association studies (GWAS) have identified numerous genes associated with ASCVD that function in the vessel wall, suggesting that vascular cells mediate ASCVD, and that the genes and pathways essential for this vascular cell function may be novel therapeutic targets for the treatment of ASCVD. Furthermore, some of these implicated genes appear to function in the adventitial layer of the vasculature, suggesting these cells are able to potentiate ASCVD. MethodsTo investigate the role of adventitial cells in atherosclerosis, we conducted single-cell RNA sequencing (scRNA-seq) of the aortic adventitia during atherogenesis in male Ldlr-/- mice via pools of three mice, two samples per condition. We cross-referenced the scRNA-seq data with human ASCVD GWAS to identify regulators of adventitial responses in ASCVD. These regulators were then validated in vitro in human adventitial fibroblasts. ResultsWe identified four adventitial fibroblast populations, all of which displayed shifts in population size and gene expression over the course of atherogenesis. SERPINH1, an ASCVD-linked GWAS gene, was differentially expressed in adventitial fibroblasts during atherogenesis. Knockdown of SERPINH1 in vitro reduced fibroblast migration and altered subcluster marker gene expression. ConclusionsThese findings reveal dynamic changes in adventitial fibroblasts during atherosclerosis and suggest that reduced SERPINH1 expression disrupts adventitial fibroblast function, contributing to ASCVD progression.

genomics↗

bioRxiv2023

Longevity-associated SMAD3 non-coding centenarian variant impairs a cell-type specific enhancer to reduce inflammation

Given the pro and anti-geronic roles of the TGF-{beta} superfamily in aging, we hypothesized that human longevity involves genetic variation in TGF-{beta} signaling genes. Here we utilized a candidate functional genomic approach to identify and characterize functional variants in TGF- {beta} signaling associated with human longevity. Targeted sequencing of 113 genes involved in aging- associated TGF- {beta} signaling in an Ashkenazi Jewish centenarian cohort identified genetic variants robustly associated with human longevity. In particular, a centenarian-enriched intronic variant residing in a cell-type specific enhancer in SMAD3, a critical receptor-regulated TGF- {beta} signal transducer, was identified. This non-coding SMAD3 variant (rs8040709) altered binding of ELK1, a member of the ETS family of transcription factor important for enhancer activity in certain cell types, resulting in reduced SMAD3 expression. Analysis of the variant in cell types derived from gene edited iPSCs demonstrated the variant reduced SMAD3 expression, senescence and inflammation in endothelial cells. In addition, heterozygosity in SMAD3 improved healthspan and reduced senescence in the Ercc1-/{Delta} progeroid mouse model of accelerated aging. Taken together, these experiments demonstrate that variants in a cell type specific enhancer of SMAD3 resulted in reduced expression, senescence and inflammation and contributes to human longevity. Thus, SMAD3 represents a validated targeted for drug development for extending human healthspan.

genetics↗